Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nanoparticle albumin-bound paclitaxel for breast cancer. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (Abraxane; Abraxis BioScience LLC, a wholly owned subsidiary of Celgene Corp.) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have metastatic breast cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometer albumin-bound nanoparticles of paclitaxel and is, therefore, free of solvents. The goals of this new nanotechnology-based formulation are to reduce toxicity and improve the bioavailability of paclitaxel. Indexing Status Subject indexing assigned by CRD MeSH Albumins; Antineoplastic Agents; Breast Neoplasmss; Paclitaxel Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000818 Date abstract record published 13/11/2013 |